Original Source(s)
Related Content
FDA Expands Guselkumab Label in PsA
Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.
May 29, 2026
-
2 min
Medical Oddities: Brain Health, Sunny-Side Up
Breakfast, bacteria, and brain wiring—small things show big implications this week.
by Teraya Smith
May 5, 2026
-
5 min